(HealthDay News) — For adults with migraine, atogepant 60mg once daily was superior to placebo for efficacy and functional measures of treatment across 3 trials, according to research published online ...
The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback